Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Neuroma, Acoustic × icotinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 10 Lung Neoplasms 3 Brain Neoplasms 3 Neuroma, Acoustic 1 Neurofibromatosis 2 1 Neoplasms 1 Neoplasm Metastasis 1 Nasopharyngeal Carcinoma 1 Esophageal Neoplasms 1 Bronchial Neoplasms 1 Adenocarcinoma of Lung 1

Interventions

Cochlear Implants 3 Radiosurgery 2 Lapatinib 2 Everolimus 2 Bevacizumab 2 tozuleristide 1 icotinib 1 Triamcinolone Acetonide 1 Temozolomide 1 Sirolimus 1 Radiotherapy, Intensity-Modulated 1 Radiotherapy, Conformal 1 Mn-PyC3A 1 Microsurgery 1 Methylprednisolone 1 Gentamicins 1 Fluoresceins 1 Fluorescein 1 Exome 1 Endostatins 1 Axitinib 1 2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02934256 2021-09-09

Icotinib

Beijing Tiantan Hospital

Phase 2 Completed

Neuroma, Acoustic, Neurofibromatosis 2

Data powered by HemOnc (CC BY 4.0) Colophon ⚡